UPSTREAM BIO, INC. Capital Expenditures Incurred but Not yet Paid
UPSTREAM BIO, INC. (UPB) reported Capital Expenditures Incurred but Not yet Paid of $55.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2025-11-05
- 2025-09-30: Capital Expenditures Incurred but Not yet Paid 9 month $55.00K.
- 2024-09-30: Capital Expenditures Incurred but Not yet Paid 9 month $133.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 9 month |
|---|---|
| 2025-09-30 | $55.00K 10-Q · filed 2025-11-05 |
| 2024-09-30 | $133.00K 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |